In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program. 

Related News Articles

Headline
In a study reported this week in JAMA Network Open, researchers found no association between a drug’s list price and research and development costs. The study…
Headline
The House today passed legislation that would suspend through 2022 tariffs on certain infant formula base powders used to make infant formula in the United…
Headline
The Senate today voted 72-25 to pass and send to the House a continuing resolution that would extend current federal funding levels for health care and…
Headline
The AHA and Federation of American Hospitals today urged Congress to oppose H.R.1330/S.4130 and any other legislation that would repeal or weaken current…
Headline
The Senate Finance Committee today released a discussion draft of legislation to expand the mental health workforce. According to a summary of the provisions,…
Headline
UnitedHealth Group may proceed with its proposal to acquire Change Healthcare, a federal district judge ruled yesterday. The Department of Justice, joined by…